Strategic Expansion Gallant is expanding in the pet health space with an off-the-shelf MSC therapy platform and plans for FDA conditional approval in 2026, signaling growing market opportunity for veterinary regenerative products and associated services.

Education Platform Launch of GallantU, an online CE platform for veterinary professionals, creates a channel to upsell training, mentorship, and adoption of regenerative medicine solutions, accelerating clinical uptake.

Key Hire Impact New Director of Veterinary Affairs strengthens engagement with veterinary clinics and practitioners, offering a direct avenue for product advocacy, protocols, and reimbursement discussions to drive adoption.

Clinical Portfolio A diverse pipeline addressing canine and feline conditions (FCGS, osteoarthritis, CKD, atopic dermatitis) enables cross-sell opportunities across clinics treating multiple chronic pet conditions with standardized, ready-to-use therapies.

Financial Readiness Recent Series B funding and a mid-range revenue profile imply capacity for channel expansion, partner programs, and scale-up activities to reach veterinary practices, clinics, and distributors.